[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-Intermediate and High-Risk Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) [frontMIND]

What is the purpose of the study? (in Layman's terms, please describe the study)

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL

Upstate Institutional Review Board (IRB) Number:

1750102

Study/Protocol ID:

MOR208C310

Study Phase:

3

Patient Age Group:

Adults

Principal Investigator:

Teresa C Gentile, MD, PhD

Where will the study take place?

SUNY Upstate Medical University

ClinicalTrials.Gov ID:

NCT04824092

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Kelsey F Christo
Phone: 315-464-5751
Email: christok@upstate.edu

Return to Previous Page || Search Again

Top